AITL

AITL applies adversarial inductive transfer learning with deep neural networks to predict drug responses from patient and cancer cell line gene expression for pharmacogenomics.

Key Features:

• Input-space discrepancy handling: Explicitly addresses differences in gene expression distributions between pre-clinical models (cancer cell lines) and human patient samples.
• Output-space discrepancy handling: Accounts for variations in drug response measures between experimental settings and clinical outcomes.
• Adversarial domain adaptation: Uses adversarial networks to align input distributions across source (cell lines) and target (patients) domains.
• Multi-task learning: Learns shared representations that jointly model source and target tasks to mitigate output-space differences.
• Predictive capability: Generates drug response predictions from single- or multi-sample gene expression data to support pharmacogenomic analyses.

Scientific Applications:

• Pharmacogenomics: Enhances translational modeling by transferring knowledge from well-characterized pre-clinical datasets to clinical patient data.
• Precision oncology: Supports development of patient-specific drug response predictions based on tumor gene expression profiles.
• Pre-clinical to clinical translation: Bridges modeling gaps between cancer cell line experiments and clinical outcome measures to improve applicability of predictive models.

Methodology:

Inputs are gene expression data from cell lines (source) and patient samples (target); training uses adversarial networks for input distribution alignment and multi-task learning frameworks to handle output-space discrepancies and produce drug response predictions.